Emplicure Interim Report Q1 2022

2022-04-26 06:30

Our objective with Amp01 is to offer an enhanced customer experience through a significantly longer release profile of both nicotine and flavor, than what exists on the market today

First quarter, 1 January – 31 March 2022

  • Net revenue totalled 0.0 (0.0) MSEK
  • EBIT totalled -7.3 (-0.9) MSEK
  • EBITDA totalled -7.3 (-1.3) MSEK
  • Cash flow totalled -5.6 (+9.5) MSEK
  • Earnings per share -0.36 (-0.12) SEK

Torbjörn W. Larsson
Phone: +46 (0)70 747 65 99
Email: torbjorn.walkerlarsson@emplicure.com

Erik Magnusson
CFO, Investor Relations
Phone: +46 (0)708 565 245
Email: erik.magnusson@emplicure.com

Emplicure AB (publ) is listed on the Nasdaq First North Growth Market. Certified Adviser is Mangold Fondkommission AB, +46 8 503 015 50, or via ca@mangold.se

This information is information that Emplicure AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The informationen was submitted for publication, through the agency of the contact persons above, on April 26, 2022 at 08:30 CET.

The following documents can be retrieved from beQuoted

Emplicure is a pharmaceutical company developing new and innovative drugs by combining existing and approved active substances, and advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain, and with abuse deterrent formulations. The wholly owned subisidiary, Amplicon AB develops consumer products, with white oral nicotine pouches as the first product. Read more at www.emplicure.com

Do you want to know more?